Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

566

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/06/26	HK$23.48	+6.05%	85,200
26/06/26	HK$22.14	-3.66%	85,500
25/06/26	HK$22.98	-2.96%	101,600
24/06/26	HK$23.68	+0.59%	120,800
23/06/26	HK$23.54	+2.71%	100,700

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

20.35CNY

Average target price

25.19CNY

Spread / Average Target

+23.78%

Consensus

Net sales - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. Other stock markets 11:08:52 29/06/2026 +03			5-day change	1st Jan Change
23.48 ^HKD	+6.05%		+2.44%	-22.97%

03:22am	Certain H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI

Market Cap	2.89B 3.33B 425M 372M 343M 320M 603M 40.14B 617M 4.13B 1.59B 19.8B 1.59B 1.56B 68.74B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	1.99B 2.29B 292M 256M 236M 221M 415M 27.64B 425M 2.84B 1.1B 13.64B 1.1B 1.07B 47.35B	EV / Sales 2026 *	2.91x	EV / Sales 2027 *	2.06x
Free-Float	23.17%	Yield 2026 *	-	Yield 2027 *	-

03:22am	Certain H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
03-31	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-09	Medtide Completes Hong Kong-Listed Share Full Circulation	MT
02-26	Medtide Forecasts Higher 2025 Profit on Back of Up to 32% Rise in Revenue	MT
02-26	Medtide Inc. Provides Preliminary Group Earnings Guidance for the Year Ended December 31, 2025	CI
02-06	Medtide Gets CSRC Nod for Hong Kong Share Full Circulation	MT
12-30	2,565,000 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025.	CI
26/09/25	Medtide Inc. Announces Change of Joint Company Secretary	CI
30/06/25	Hong Kong Stocks Drop as China Factory Struggles Persist; Unisound, IFBH, Medtide Shine on Debut	MT
30/06/25	Medtide Slips 1% in Quiet Hong Kong Debut	MT
30/06/25	Medtide Nets HK$429 Million from Hong Kong IPO, Prices Shares at Upper Limit of Guidance	MT
27/06/25	Medtide Inc. has completed an IPO in the amount of HKD 514.08 million.	CI

1 day	+6.05%
1 week	+2.44%
Current month	+8.00%
1 month	+8.00%
3 months	+4.63%
6 months	-21.31%
Current year	-22.97%

Medtide Inc. Stock

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news : Medtide Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Net sales - Rate of surprise

1 week	22	24.2
1 month	19	24.5
Current year	19	30.46
1 year	19	41.72
3 years	19	41.72
5 years	19	41.72
10 years	19	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	11/06/2020
Wei Qun Xu DFI	Director of Finance/CFO	53	01/10/2020
Ling Mei Li IRC	Investor Relations Contact	50	01/09/2023

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	11/06/2020
Xiang Li Li BRD	Director/Board Member	51	27/01/2022
Xiang Li BRD	Director/Board Member	63	27/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-09	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%
03-09	Xiang Li Li	Other	Director	68,201,112	48.0967%
03-09	Xiang Li Li	Other	Director	68,201,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+6.05%	+2.44%	-	-	400M
LONZA GROUP AG	+0.94%	+7.83%	-4.77%	+3.17%	46.2B
REVOLUTION MEDICINES, INC.	+5.79%	+16.17%	+421.86%	+634.63%	38.71B
IQVIA HOLDINGS INC.	+1.12%	+15.18%	+22.74%	-12.71%	31.9B
BEONE MEDICINES AG	+3.61%	+6.69%	+20.23%	+62.38%	31.12B
CELLTRION, INC.	+8.02%	+5.23%	+17.67%	+35.36%	23.77B
ASCENDIS PHARMA A/S	+1.13%	+15.66%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+1.45%	+17.35%	+72.11%	+127.60%	15.05B
EUROFINS SCIENTIFIC SE	-1.13%	+7.40%	+12.03%	+20.67%	13.74B
IONIS PHARMACEUTICALS, INC.	-0.60%	+6.32%	+102.74%	+96.28%	13.42B
Average	+2.64%	+10.19%	+83.08%	+120.92%	23.05B
Weighted average by Cap.	+2.71%	+11.40%	+95.90%	+142.98%

	2026 *	2027 *
Net sales	684M 789M 101M 88.11M 81.34M 75.96M 143M 9.51B 146M 979M 378M 4.69B 378M 370M 16.3B	876M 1.01B 129M 113M 104M 97.23M 183M 12.18B 187M 1.25B 484M 6.01B 484M 473M 20.86B
Net income	-	-
Net Debt	-898M -1.04B -132M -116M -107M -99.72M -188M -12.49B -192M -1.29B -496M -6.16B -496M -485M -21.39B	-1.08B -1.25B -159M -139M -129M -120M -226M -15.03B -231M -1.55B -597M -7.42B -597M -584M -25.75B